

**Amendments to the Claims (No amendments):**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-28. (Canceled)

29. (Previously presented) A purified monoclonal antibody which specifically binds to a *patched-2* polypeptide of SEQ ID NO:2 or to a variant of said polypeptide having at least 95% sequence identity, wherein said *patched-2* polypeptide binds to a *hedgehog* polypeptide.

30. (Previously presented) The antibody of Claim 29, wherein the *patched-2* polypeptide comprises amino acid residues 1 to 1203 of SEQ ID NO:2.

31-35. (Cancelled).

36. (Previously presented) The antibody of Claim 29 which is humanized.

37. (Previously presented) The antibody of Claim 29 which is bispecific.

38. (Previously presented) The antibody of Claim 29 which is heteroconjugated.

39. (Previously presented) A purified monoclonal antibody which specifically binds to a *patched-2* polypeptide of SEQ ID NO:2 or to a variant of said polypeptide having at least 95% sequence identity, wherein said *patched-2* polypeptide binds to a *Smoothened* polypeptide.

40. (Previously presented) The antibody of Claim 39, wherein the *patched-2* polypeptide comprises amino acid residues 1 to 1203 of SEQ ID NO:2.

41-45. (Cancelled)

46. (Previously presented) The antibody of Claim 39 which is humanized.

47. (Previously presented) The antibody of Claim 39 which is bispecific.

48. (Previously presented) The antibody of Claim 39 which is heteroconjugated.

49. (Previously presented) A purified monoclonal antibody which specifically binds to the *patched-2* polypeptide encoded by the human cDNA insert of the polynucleotide deposited under ATCC 209778.

50-51. (Cancelled).

52. (Previously presented) The antibody of Claim 49 which is humanized.

53. (Previously presented) The antibody of Claim 49 which is bispecific.

54. (Previously presented) The antibody of Claim 49 which is heteroconjugated.